Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
المؤلفون المشاركون
Cakir, Akin
Erden, Burak
Bolukbasi, Selim
Baş, Emine
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-10-31
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Purpose.
To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV).
Methods.
The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively.
All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR.
Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment.
Results.
There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years.
The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm at Month 12 (p:0.024 and p:0.011, respectively).
There were 18 eyes in IVR group, with a mean age of 57.4 ± 13.1 years.
The mean BCVA improved from baseline 1.14 ± 0.90 to 1.04 ± 0.93 and the mean CMT significantly decreased from baseline 366.5 ± 102.3 μm to 323.6 ± 103.6 μm at Month 12 after IVR (p:0.345 and p:0.011, respectively).
There was no significant difference between the groups in CMT changes in the study period (p:0.178), but IVA resulted in significantly better final visual gain (0.69 versus 0.09; p:0.006).
Conclusions.
Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Erden, Burak& Bolukbasi, Selim& Baş, Emine& Cakir, Akin. 2019. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Erden, Burak…[et al.]. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Erden, Burak& Bolukbasi, Selim& Baş, Emine& Cakir, Akin. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1186313
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر